AngioDynamics Stock News

Zacks Investment Research lowered shares of AngioDynamics (NASDAQ:ANGO) from a strong-buy rating to a hold rating in a research report report published on Wednesday, Zacks.com reports. The brokerage currently has $27.00 target price on the medical instruments suppliers stock. According to Zacks, AngioDynamics uptick in year-over-year revenues and solid performances across two of its GBUs []

Comerica Bank trimmed its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 7.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,852 shares of the medical instruments suppliers stock after selling 2,877 shares during the quarter. Comerica Banks holdings in AngioDynamics were worth []

Zacks Investment Research cut shares of AngioDynamics (NASDAQ:ANGO) from a strong-buy rating to a hold rating in a research report sent to investors on Wednesday, Zacks.com reports. The brokerage currently has $27.00 price objective on the medical instruments suppliers stock. According to Zacks, AngioDynamics uptick in year-over-year revenues and solid performances across two of its []

Varicose Vein Treatment Market 2021 Overview: This research report categorizes the Varicose Vein Treatment market by top vendors, region, type, and end-user. this report also lessons the global Varicose Vein Treatment market status, competitive landscape and analysis, market size and share,

AngioDynamics (NASDAQ:ANGO) and Invo Bioscience (OTCMKTS:IVOB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends. Volatility and Risk AngioDynamics has a beta of 0.86, suggesting that its stock price is 14% []

Metropolitan Life Insurance Co NY increased its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 96,900.0% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 11,640 shares of the medical instruments supplier’s stock after acquiring an additional 11,628 shares during the quarter. Metropolitan Life Insurance Co NY’s holdings in AngioDynamics were worth $316,000 at […]

Royal Bank of Canada reduced its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 22.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,693 shares of the medical instruments suppliers stock after selling 25,129 shares during the quarter. Royal Bank of Canadas holdings in []

Amalgamated Bank bought a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 18,070 shares of the medical instruments suppliers stock, valued at approximately $490,000. Other hedge funds and other institutional investors have also added to or []

Goldman Sachs Group Inc. grew its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 78.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 228,540 shares of the medical instruments suppliers stock after buying an additional 100,214 shares during the quarter. Goldman Sachs Group []

Data Bridge Market research presents the top quality and comprehensive Ablation technology research report which provides clear insights into market dynamics and prospects the whole market including global production, revenue forecast, value and volume. This Ablation technology report deeply

Canada Varicose Vein Treatment Devices Market: Overview As per the study published in NCBI or National Centre for Biotechnology Information, over 3.7 million people in Canada are living with varicose veins. This has considerably heightened the need for effective and enhanced

The medical devices company beat analyst expectations in the first quarter of its new fiscal year. Could it be a buy?

AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.

AngioDynamics Inc  (NASDAQ: ANGO) reported a Q1 FY22 adjusted EPS loss of $(0.02), ahead of the consensus of $(0.04). Q1 sales increased 9.6% Y/Y to $77 million, beating the analyst consensus of $

AngioDynamics, Inc.'s (ANGO) CEO Jim Clemmer on Q1 2022 Results - Earnings Call Transcript